News - Takeda Pharmaceuticals


Current filters:

Takeda Pharmaceuticals

Popular Filters

40 to 64 of 192 results

US Priority Review for Takeda's vedolizumab for ulcerative colitis


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) says that the US Food and Drug Administration…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Santhera regains Catena European rights


Switzerland-based Santhera Pharmaceuticals (SIX: SANN) says that it has reached an agreement with Takeda…

CatenaEuropeLicensingPharmaceuticalRare diseasesSanthera PharmaceuticalsTakeda Pharmaceuticals

Further highlights from European Society of Cardiology meeting


The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Takeda further expands presence in Latin America


Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502), through its Switzerland-based international…

Markets & MarketingPharmaceuticalSouth AmericaTakeda Pharmaceuticals

Takeda's vedolizumab shows efficacy in colitis and Crohn's disease


A new investigational antibody - vedolizumab - from Japan's largest drugmaker, Takeda Pharmaceuticals…

Gastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Takeda gains first European approval for lurasidone


Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

Lundbeck/Takeda's Brintellix has blockbuster potential


Denmark CNS drug specialist Lundbeck (LUND: CO) and partner Japanese drug major Takeda Pharmaceutical's…

BrintellixedivoxetineEli LillyFetzimaForest LaboratoriesGenericsGlobalLundbeckMarkets & MarketingNeurologicalPharmaceuticalPierre FabreTakeda Pharmaceuticals

Top-line financials for Japanese drug majors


Among a flurry of first-quarter fiscal 2013/14 financial results released by Japanese drug majors, the…

Dainippon Sumitomo PharmaEisaiFinancialMitsubishi TanabePharmaceuticalTakeda Pharmaceuticals

Takeda gains Chinese approval for diabetes drug


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), says that the China Food and Drug Administration…

Asia-PacificDiabetesNesinaPharmaceuticalRegulationSanofiTakeda Pharmaceuticals

Disappointment for Takeda as Ph III prostate cancer trial fails


Japan's largest drugmaker Takeda Pharma (TYO: 4502) has unblinded a Phase III study after analysis showed…

Asia-PacificMen's HealthOncologyorteronelPharmaceuticalResearchTakeda Pharmaceuticals

Three of Takeda's diabetes therapies get positive opinion from EMA unit


Japan's largest drugmaker Takeda (TSE: 4502) has received a positive opinion from the European Medicines…

DiabetesEuropeIncresyncPharmaceuticalRegulationTakeda PharmaceuticalsVipdometVipidia

Evolution of Japan's pharma wholesalers - by P Reed Maurer


Half of the definition for evolution (noun; a gradual process in which something changes especially into…

Asia-PacificFinancialMitsubishi TanabePharmaceuticalProductionSankyoShionogiTakeda Pharmaceuticals

$10 million milestone for Sucampo, as Takeda starts US selling of Amitiza for OIC


USA-based Sucampo Pharmaceuticals (Nasdaq: SCMP) says that it has received a $10 million milestone payment…

AmitizaFinancialGastro-intestinalsMarkets & MarketingNorth AmericaPharmaceuticalSucampoTakeda Pharmaceuticals

Takeda files BLA for vedolizumab for Crohn's and ulcerative colitis in USA


The US subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has submitted a Biologics…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says that its new diabetes products Nesina…

DiabetesKazanoMarkets & MarketingNesinaNorth AmericaOseniPharmaceuticalTakeda Pharmaceuticals

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso


French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

Is the diabetes market facing a blockbuster-free future?


Japanese drug major Takeda's (TYO: 4502) recently announced positive late-stage results for new type…

DiabetesfasiglifamMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceuticals

Lundbeck and Takeda's Brintellix shows positive results in Ph III major depression study


Danish CNS specialist Lundbeck (LUND: DC) and partner Takeda Pharmaceutical (TYO: 4502), Japan's largest…

BrintellixLundbeckNeurologicalPharmaceuticalResearchTakeda Pharmaceuticalsvortioxetine

Top-line financial results from Japanese drug majors


Among a batch of Japanese drug majors presenting fiscal year 2013 (ended April 2013) financial results,…

Dainippon Sumitomo PharmaFinancialMitsubishi TanabePharmaceuticalShionogiTakeda Pharmaceuticals

Takeda to acquire Inviragen, gaining rights to promising vaccines


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into a definitive agreement to…

DENVaxInviragenMergers & AcquisitionsPharmaceuticalTakeda PharmaceuticalsVaccines

US Judge throws out verdict in Takeda Actos case


The US subsidiary of Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) USA announced that,…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

40 to 64 of 192 results

Back to top